Causes, Complications and Outcomes of Severe Acute Liver Disease Cases Admitted to Intensive Care Units
Colección de datos
Otro
Uso de métodos específicos que no están cubiertos por los modelos estándar para abordar preguntas de investigación únicas.Resumen
Fecha de inicio: 20 de junio de 2023
Fecha en la que se inscribió al primer participante.The main objectives of this observational study are: 1. To evaluate cases of (ALF) and (ACLF) according to guidelines. 2. To determine most likely causes of disease in a patient of each age. 3. To determine complications of disease. 4. Assesment of mortality and morbidity rates. 5. Assessment of in-hospital and six month follow up outcomes according to guidelines. Participants (or their designated contact persons) will be contacted over the phone for either a telephone interview or a follow-up visit in the outpatient clinics, whichever feasible and possible. All patients presented with severe acute liver disease, acute liver failure (ALF) and acute on chronic liver disease (ACLF). 1. Inclusion criteria: 1. reduced conscious state 2. Jaundice with abnormal liver function tests, especially elevations in amino acid transferase levels more than 25 times the upper limit of normal 3. Coagulopathy 4. Multiorgan failure 2. Exclusion criteria: Patients with these criteria will be excluded: 1. Patients with known cardiac cirrhosis. 2. Patients with known pre-existing renal disease * Study tools All patients will be subjected to: 1. Thorough history taking (History of previous renal disease, severe co-morbidity, malignancy, …). 2. Thorough clinical examination 1. Vital signs. 2. General examination. 3. Systemic examination: * Chest examination. * Cardiac examination. * Abdominal examination. * Neurological examination. 3. Imaging 1. Abdominal ultrasound with especial comment on kidneys and intra-abdominal fluid. 2. Chest x-ray 3. Echocardiography 4. Laboratory investigations 1. Liver function tests: alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), serum bilirubin, prothrombin time (PT) and albumin. Before and after end of treatment. 2. Serum creatinine: Before and after end of treatment 3. Urine analysis: Before and after end of treatment 4. Albumin creatinine ratio: Before and after end of treatment 5. Measuring body weight Before and after end of treatment 6. Special scores (CLIF-SOFA /CLIF-C OFs /DF /ABIC /GAHS /MELD /MELD-Na /CHILD)
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 200 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Otro
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.De 18 a 75 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Criterios
Plan de Estudio
Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.Objetivos del Estudio
Objetivos Primarios
Objetivos Secundarios